Barclays lowered the firm’s price target on Addus HomeCare (ADUS) to $112 from $117 and keeps an Underweight rating on the shares. The firm updated the company’s model post the Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus Homecare: Strong Core Growth, Expanding Margins, and Upside from Hospice Momentum Support Buy Rating
- Addus HomeCare Reports Strong Q4 and Full-Year Results
- Addus HomeCare reports Q4 adjusted EPS $1.77, consensus $1.73
- Is ADUS a Buy, Before Earnings?
- Addus HomeCare initiated with a Buy at Truist